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Regulation of parathyroid hormone synthesis in chronic renal
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Regulation of parathyroid hormone synthesis in chronic renal failure in
rats. To clarify the mechanism of secondary hyperparathyroidism in
chronic renal failure at the parathyroid hormone (PTH) synthesis level,
we measured PTH messenger RNA (mRNA) levels in parathyroid
glands in a rat model of chronic renal failure. Four weeks after 7/8
nephrectomy, hyperplasia of parathyroid glands was evident and serum
PTH levels were elevated. Serum concentration of calcium, inorganic
phosphate, and I ,25-dihydroxyvitarnin 0 (1 ,25(OH)2D) of rats with
chronic renal failure were not detectably different from those of
sham-operated rats. In chronic renal failure rats, PTH mRNA levels
were elevated both per RNA and per DNA of parathyroid cells,
suggesting increased PTH mRNA levels per cell. The elevated levels of
PTH mRNA were returned to normal levels by achieving supraphysi-
ological concentrations of 1 ,25(OH)2D3 given i.p. twice at 24 and 48
hours before sacrifice, although this was attended by slight hypercalce-
mia. A synthetic analogue of vitamin D, 22-oxa-l ,25(OH)2D3, also
suppressed PTH mRNA to normal levels, but without hypercalcemia.
These data suggest that secondary hyperparathyroidism in early
chronic renal failure may be due in part to the resistance of parathyroid
cells to the physiological concentration of 1 ,25(OH)2D in circulation on
PTH synthesis and that 22-oxa-l ,25(OH)2D3 may be useful in the
management of secondary hyperparathyroidism of chronic renal failure.
Secondary hyperparathyroidism is one of the major factors
underlying bone diseases of chronic renal failure [1]. It has been
suggested that decreased serum ionized calcium and skeletal
resistance to parathyroid hormone (PTH), probably due to
reduced production of 1,25-dihydroxyvitamin D (l,25(OH)2D),
are the major stimuli for enhanced PTH secretion in chronic
renal failure [21. However, these postulates have been depen-
dent principally on the observations on changes in plasma PTH
levels and PTH secretion. Recent reports suggest that synthesis
of PTH at the transcriptional level as well as its secretion are
regulated by serum calcium and 1 ,25(OH)2D in vitro [3—5] and
in vivo [6, 7] in animals with normal renal function. Based on
these observations, it is thought that long term stimulation of
PTH secretion by decreased concentration of serum calcium or
1 ,25(OH)D may lead to the enhancement of PTH synthesis in
chronic renal failure. Indeed, a recent study by Shvil and
associates have shown that not only PTH secretion is increased
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but also PTH synthesis, as judged by the changes in the levels
of PTH messenger RNA (mRNA), is increased in rats with
chronic renal failure rats, and suggest that this is probably due
to reduced plasma levels of 1 ,25(OH)2D [8]. A series of studies
by Slatopoisky and associates [9—11] have suggested that the
pathogenesis of secondary hyperparathyroidism of chronic ure-
mia may be more complicated. Thus, their data in chronic
dialysis patients indicate that physiological concentrations of
l,25(OH)2D in circulation may not be able to suppress severe
secondary hyperparathyroidism of chronic uremia, but, inter-
mittent administrations of 1 ,25(OH)2D by i.v. or by p.o. [12]
could suppress the secondary hyperparathyroidism of chronic
uremia with improvements of bone disease [13] and even with
correction of the set-point of PTH secretion for ambient cal-
cium which was shifted to the right [10]. Since 1 ,25(OH)2D
receptors are present in parathyroid glands and the receptor
density may be reduced in parathyroid glands of chronic uremic
patients [14], these data may suggest that transient supraphys-
iological, and not physiological, concentrations of 1 ,25(OH)2D,
which could be achieved by intravenous or oral pulse
1 ,25(OH)2D3 administration, may lead to binding of 1 ,25(OH)2D
to the receptor, and suppress PTH secretion in uremia. These
data may explain the mechanisms for the resistance of parathy-
roid cells to the physiological concentration of 1 ,25(OH)2D. In
addition to these observations, Brown and associates have
recently shown in rats with normal renal function that 22-oxa-
l,25(OH)2D3, an analogue of 1,25(OH)2D, which shares cell
differentiating action but not calcemic action of 1 ,25(OH)2D3,
may suppresses PTH secretion and synthesis [15]; however, it
is not known whether this vitamin D analogue suppresses PTH
synthesis and secretion in chronic uremia. To gain further
insights into the pathogenesis of secondary hyperparathyroid-
ism of chronic renal failure, especially in its early phase, we
carried out a series of studies to evaluate the regulations of
vitamin D on PTH synthesis using a model of chronic renal
failure in rats. Specifically, we analyzed the steady state levels
of PTH mRNA, the initial step of PTH synthesis, in rats with
7/8 nephrectomy for four to six weeks and examined the effects
of 1,25(OH),D3 and 22-oxa-l,25(OH)2D3 given in vivo.
Methods
Preparation of animals
A rat model of chronic renal failure was prepared by 7/8
nephrectomy with a standard two step operation. Briefly, male
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Sprague-Dawley rats (11 weeks old), weighing about 350 g and
fed standard chow (calcium 0.6%, phosphorus 0.6%; Nihon
Clea, Tokyo, Japan), were anesthetized by diethyl ether and
three of four branches of the left renal artery were ligated with
dorsal approach. One week later, the right renal artery was
ligated under light ether anesthesia. After at least four weeks
following the second operation, partially nephrectomized rats
were used as a model of early phase of chronic renal failure. In
sham-operated rats, both kidneys were decapsulated and bilat-
eral renal arteries were separated from veins and ureters. They
were pair-fed and served as controls. When indicated, vitamin
D metabolites dissolved in 400 d of propylene glycol or vehicle
alone were given intraperitoneally (i.p.) at both 24 and 48 hours
before sacrifice. l,25(OH)2D3 was supplied by Roussel
UCLAF, Paris, France, and 22-oxa-l,25(OH)2D3 by Chugai
Pharmaceutical, Tokyo, Japan.
Measurement of PTH mRNA
Total cellular RNA was extracted from thyro-parathyroid
glands of one rat each or from combined parathyroid glands of
five rats as specified in Results. These glands were homogenized
in 4 M guanidinium thiocyanate and centrifuged on 5.7 M cesium
chloride (CsCI) cushion at 100,000 g for 18 hours at 20°C. RNA
was then dissolved in 0.3 M sodium acetate and precipitated by
ethanol at —80°C [16]. Cellular DNA was simultaneously puri-
fied by phenol extraction from the supernatant fraction that
stayed above the CsC1 cushion [17]. Amounts and purities of
RNA and DNA were evaluated by reading absorbance at 260
nm and at 280 nm [181. Recovery of total RNA from thyropar-
athyroid glands per rat was about 25 to 30 g.
PTH mRNA was detçcted by Northern blot and the primer
extension methods. Two oligonucleotides were synthesized by
automated DNA synthesizer (Model 8700; Biosearch, San
Rafael, California, USA): the sequence of one is 5'-CCTGTAT-
TAAGCTGGAGTAAGCCAGACAGC-3 which is complemen-
tary to the 50th to 79th nucleotides of rat PTH mRNA [19], and
the sequence of the other is 5'-CGCCCGCGAAGCCGGCCT-
TGCACATGGCGG-3 which is complementary to the 12 1st to
150th nucleotides of rat 13-actin mRNA [20]. Aliquots (0.1 sg
each) of each oligonucleotide were 5'-end-labelled by incuba-
tion for one hour at 37°C with y-32P adenosine triphosphate
(Amersham Japan, Tokyo) and T4 polynucleotide kinase
(Takara Shuzo, Kyoto, Japan). For detecting J3-actin by North-
ern blot, 0.44kb Hinf fragments of human f3-actin cDNA was
used. Labeling of the cDNA was carried out by nick translation
using a kit (Amersharn Japan, Tokyo, Japan) and a-32P dCTP
(Amersham Japan).
For Northern blot analysis, 10 g of total RNA was size
fractionated using 1% agarose (FMC BioProducts, Rockland,
Maine, USA), 2.2 M formaldehyde denaturing gels [21]. BlOt-
tings of the agarose gel were performed based on a capillary
action method onto Biodyne Transfer Membranes (Pall UI-
trafine Filtration Corp., Glen Cove, New York, USA) and the
filter was baked at 80°C for two hours. Prehybridization solu-
tion was 50% formamide, 5 x SSC (1 X SSC: 0.15 M NaCl,
0.015 M sodium citrate; pH 7.0), 10 x Denhardt's solution (1 x:
0.02% bovine serum albumin, 0.02% polyvinylpyrolidone,
0.02% Ficoll), 0.1% sodium dodecyl sulfate (SDS). Hybridiza-
tion solution was 1 ml in volume and was identical to prehy-
bridization solution except for further addition of either 100 ng
of 5'-labelled PTH probe (specific activity, 5 x 108 cpmIzg) or
300 ng of nick translated actin cDNA (specific activity, 3 x 108
cpmIsg), and fragmented salmon sperm DNA (100 ng/ml).
Prehybridization was carried out for four hours at 42°C, and
hybridization at 42°C for 12 hours. Washes were performed
with 1 x SSC, 0.1% SDS, three times at room temperature,
then with 0.1 x SSC, 0.1% SDS for 30 minutes at 42°C.
Autoradiography exposure was carried out for two days with
two intensifying screens at —80°C.
For the primer extension method, both I to 5 pg of the
labelled PTH and f3-actin primer (5 x 108 cpm//sg each) were
mixed and hybridized with 10 tg or indicated quantities of each
RNA sample in 20 sl of 10 msi PIPES (piperazine-N,N'-bis-
ethane-sulfonic acid, pH 6.4) and 0.4 M sodium chloride at 62°C
for two hours, and then extended by incubating with 10 units of
reverse transcriptase (Seikagaku Kogyo, Tokyo, Japan) in 20 p1
of 50 mi Tris-HCI (pH 8.3), 8 m MgCI2, 50 m KC1, 100mM
dithiothreitol, and 10 m dNTP at 42°C for one hour [22]. These
extended nucleotides, 79 base pairs (bps) for PTH mRNA and
150 bps for f3-actin, were analyzed by electrophoresis in 8%
polyacrylamide gel containing 7 M urea after heat denaturing,
and were exposed to films at —80°C. Autoradiograms were
scanned with densitometer (Digital Densitorol DMU-33C; Toyo
Kogaku Sangyo, Tokyo, Japan). For quantitative analyses, the
ratio of density of the PTH mRNA band to that of the 13-actin
mRNA band on the same lane was calculated.
To assess the thyroid contamination in the cellular RNA from
parathyroid glands, thyroglobulin mRNA was detected by dot
blot using synthetic oligonucleotide complementary to the
sequence between 91st and 120th nucleotide of rat thyroglobu-
un gene exon 1 [23]. The sequence is 5'-TCAACAAAGTC-
GAGACCCACAAGACCAAGG-3'. Briefly, 10 sg of cellular
RNA from parathyroid glands or 1, 2.5, or 5 g of cellular RNA
from thyroid glands were applied to the well (Minifold I,
Schleicher and Schuell, Inc., Dassel, Germany) and transferred
to the nitrocellulose membrane (Cellulosenitrate BA85, Schie-
icher and Schuell, Inc.) by gentle vacuum suction [24]. The
membrane was baked at 80°C for two hours and then hybridized
with the 5'-labelled thyroglobulin probe. The conditions of
hybridization and washing were same as for the Northern blots
of PTH mRNA described above.
Other measurements and statistical analyses
Blood samples were taken from ocular orbit or from abdom-
inal aorta at sacrifice. Serum urea nitrogen, creatinine, calcium,
inorganic phosphate and albumin were determined by Hitachi
Model 736 autoanalyzer. PTH was measured by a double
antibody method using an antibody to human PTH [44—68]
(Immuno Nuclear Corporation, Stillwater, Minnesota, USA)
[251 with rat mid-molecule PTH as standard as specified by the
supplier. It is of note that Finch and associates have recently
developed a more accurate assay for amino-terminal P1'H in the
rat [26]; unfortunately, this assay has not been available to us.
Vitamin D metabolites were assayed as follows: in brief,
vitamin D metabolites were extracted three times from 1 ml of
serum by adding 2 ml of ethyl acetate. After dehydration by
anhydrous sodium sulfate, the extract was evaporated and
resuspended in n-hexane-isopropanol (96:4) and applied to a
prewashed Sep-Pak silica cartridge (Japan Waters Associates,
Tokyo, Japan) [27]. After 25(OH)D was eluted with 10 ml of
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Table 1. Serum biochemistries in chronic renal failure and sham-
operated rats at four weeks after 7/8 nephrectomy
Chronic Sham-
renal failure operated
rats rats
Number of animals 9 9
Urea nitrogen, mg/dl 43.7 6.3a 13.4 2.7
Creatinine, mg/dl 0.9 0.04a 0.4 0.02
AlbUmin, gIdi 2.5 0.06 2.6 0.03
Calcium, mg/dl 10.4 0.09 10.2 0.12
Inorganic phosphate, mg/dl 6.5 0.32 6.6 0.14
PTH, pinol/liter 198 ll.7a 157 6,67
Body weight, g 484 8.la 516 10.0
Values are means SE.
a P < 0.05 vs. sham operated rats.
n-hexane-isopropanol (96:4), dihydroxy metabolites of vitamin
D were eluted by adding 8 ml n-hexane-isopropanol (80:20).
Eluates containing both 1 ,25(OH)2D and 24,25(OH)2D were
evaporated, redissolved in n-hexane-isopropanol (92.5:7.5), and
applied to a Radical-Pak pPorasil high performance liquid
chromatography (HPLC) column (0.8 x 10 cm; Japan Waters
Associates), and eluted with the same solvent at a flow rate of
2 mI/mm. Fractions containing 1 ,25(OH)2D were collected and
assayed for 1 ,25(OH)2D using a radioreceptor assay kit (Ya-
masa Shoyu Co., Tokyo, Japan) [28]. Fractions containing
24,25(OH)2D were combined, evapprated, resuspended in di-
chioromethane-isopropanol (98:2), and rechromatographed on a
Radical-Pak pPorasil HPLC column with djchloromethane-
isopropanol (98:2) as a solvent. The 24,25(OH)2D fractions from
the second HPLC system were collected and subjected to a
competitive protein binding assay using vitamin D-deficient rat
serum [291.
Results were expressed as means SE and the statistical
significance was determined by unpaired or paired t-test as
appropriate. P values less than 0.05 were considered significant.
Results
Four weeks after 7/8 nephrectomy, serum urea nitrogen rose
from 13.4 2.7 to 43.6 6.3 mg/dl and serum creatinine rose
from 0.44 0.02 to 0.91 0.04 mgldl (Table 1). Hypertrophy of
the remnant kidney was visibly apparent. These animals can be
regarded as a model of an early phase of chronic renal failure.
Serum levels of calcium, inorganic phosphate, albumin, and
thus presumably ionized calcium were not different between
chronic renal failure and sham-operated normal rats. We did not
determine serum ionized calcium concentration in the present
study, which may be affected by metabolic acidosis of chronic
renal failure. However, in the absence of the differences in
concentrations of albumin and total calcium between renal
failure and normal rats, the presence of acidosis, if present, in
chronic renal failure may cause a higher serum ionized calcium
which may suppress, rather than stimulate, PTH synthesis.
Serum PTH was slightly elevated in chronic renal failure rats,
but there was no reduction in serum levels of 25(OH)D,
1,25(OH)2D or 24,25(OH)2D (Fig. 1). Parathyroid glands of
chronic renal failure rats were visibly enlarged and hyperplasia
of parathyroid glands was observed histologically (data not
shown).
As shown in Figure 2, PTH mRNA levels in extracts of
thyroparathyroid glands were increased at four weeks of
chronic renal failure. The ratio of PTH mRNA to actin mRNA
increased to 326.5 42.0% of that of sham-operated rats (5
separate experiments). To make certain that the changes in
PTH mRNA in thyroparathyroid glands reflect the changes in
parathyroid glands, total RNA extracted only from parathyroid
glands from five rats were stocked and analyzed by Northern
blot. As shown as representative results in lanes 1 and 2 of
Figure 3A, PTH mRNA levels from parathyroid glands clearly
increased in chronic renal failure rats. The increase of PTH
mRNA/actin mRNA ratio was more than 10-fold (10.8
0.15-fold: 4 separate experiments) of that of sham-operated
rats. Actin mRNA levels were not significantly different be-
tween uremic and sham-operated rats (4 separate experiments).
Since secondary hyperparathyroidism of chronic renal failure is
associated with marked parathyroid cell proliferation, we next
determined PTH mRNA levels for the same amount of DNA
extracted simultaneously from parathyroid glands as a marker
of cell number. As shown in Figure 3A, lanes 3 and 4, the PTH
mRNA levels were elevated to more than 10 fold (10.1
0.46-fold, 3 separate experiments), suggesting that PTH mRNA
levels are increased per single cell in hyperplastic parathyroid
glands of uremic rats. There is a possibility that parathyroid
glands may be contaminated by thyroid glands, especially in
sham-operated rats in which parathyroid glands are not en-
larged. When we examined the contamination of thyroid gland
by using thyroglobulin mRNA, the thyroglobulin mRNA levels
in 10 p.g of cellular RNA preparations from "parathyroid
glands" of chronic renal failure and normal rats represent less
than equivalent of 1 g of RNA from thyroid tissue as shown in
Figure 3B. Thus, contamination by thyroid tissue in our results
can be negligible for the purpose of our present study.
We next evaluated the effects of vitamin D metabolites on the
PTH mRNA level of chronic uremic rats by Northern blot and
the primer extension methods. As shown in Figure 4A, phar-
macological doses of 1 ,25(OH)2D3 suppressed the elevated
PTH mRNA levels in a dose-dependent manner. Occasionally,
some slight bands other than the main 79 bps band for PTH and
the 150 bps band for actin were seen on the film by the primer
extension method even without any evidence of massive RNA
degradation as shown in the Northern blot in Figure 1. These
bands are considered to be incompletely extended primers or
the products due to non-specific priming event, thus the densi-
ties of the main band were compared as reported previously [6].
Even when densities of these incomplete band were combined
to the density of the main band, the PTH mRNA/actin mRNA
ratios thus calculated were not different from the values ob-
tained with the main bands only. Forty pmoIllOO g body weight
(body wt) of 1 ,25(OH)2D3 per day was given i.p. twice at 24 and
48 hours to five chronic renal failure rats before sacrifice. This
regimen was always sufficient to return the elevated PTH
mRNA/actin mRNA levels to the level not different from those
seen in normal rats (112.2 6.9%: when the ratio of sham-
operated rats was taken as 100%; Fig. 4B). Serum PTH levels
were also returned from 200.5 8.3 pmol/liter to normal levels
138.7 6.7 pmoLlliter). Serum concentrations of 1 ,25(OH)2D in
rats given this dose of 1 ,25(OH)2D3 rose to more than 400 pg/ml
at the time of sacrifice. Serum calcium levels at the time of
sacrifice increased in chronic renal failure rats and the increases
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Fig. 3. PTH mRNA levels in parathyroid glands of chronic renal
failure rats. In each experiment, parathyroid glands from 5 rats were
combined, extracted and applied to each lane. A. Lanes 1 and 2: 5 g of
total RNA from parathyroid glands of chronic renal failure (lane 1) and
sham-operated rats (lahe 2). Lanes 3 and 4: total RNA per 10 g of
DNA simultaneously extracted from parathyroid glands of chronic
renal failure (lane 3) and sham-operated rats (lane 4). PTH mRNA levels
are increased in chronic renal failure rats in both series. B. Thyroid
contamination judged by thyroglobulin mRNA in cellular RNA from
parathyroid glands. Lane 5: 10 g of total RNA from parathyroid glands
of chronic renal failure rats. Lane 6: 10 g of total RNA from
parathyroid glands of sham-operated rats. Lanes 7 to 9: 1 g (lane 7),
2.5 sg (lane 8), and 5 g (lane 9) of total RNA from thyroid glands.
Contamination of thyroid gland in 10 g of total RNA from parathyroid
glands in both series were no more than 1 g of total RNA from thyroid
glands.
concentration also fell in response to 22-oxa- 1 ,25(OH)2D3 to
levels (141.2 13.0 pmol/liter) seen in normal control rats. In
contrast to 1 ,25(OH)2D3; however, serum calcium concentra-
tions did not increase in chronic renal failure rats given 22-oxa-
1 ,25(OH)2D3 (Fig. 7), although the magnitudes of suppression
of PTH mRNA by these doses of 1 ,25(OH)2D3 and 22-oxa-
1 ,25(OH)2D3 were comparable. These data strongly suggest
that 22-oxa-l,25(OH)2D3 could suppress PTH mRNA levels
without hypercalcemia, as shown in rats with normal renal
function [151, even in chronic renal failure rats.
Discussion
Fig. 2. PTH mRNA levels at 4 weeks after 7/8 nephrectomy. PTH
mRNA levels were detected by Northern blot and /3-actin mRNA was
shown as a reference. Ten micrograms of total RNA from thyropar-
athyroid glands of a chronic renal failure (lane 1) and a sham-operated
rat (lane 2) were applied. PTH mRNA level is elevated in chronic renal
failure rats compared to that of sham-operated rats.
in serum calcium were greater in renal failure than in normal
rats (Fig. 5).
A synthetic metabolite of vitamin D, 22-oxa-1,25(OH)2D3,
given i.p. at a dose of 200 pmolIlOO g body wt per day for two
days prior to sacrifice to four chronic renal failure rats, also
returned the PTH mRNA to actin mRNA ratio to normal (85.4
0.7% of sham-operated rats) (Fig. 6A, B). Serum PTH
Secondary hyperparathyroidism accompanied by hyperplas-
tic parathyroid glands is a key pathogenetic factor of bone
diseases of chronic renal failure [1, 2]. It is thought that
hypocalcemia and a shift of the set-point of PTH secretion are
the major stimuli for enhanced PTH secretion in chronic renal
failure [2, 10, 11]. Recent studies demonstrated that not only
PTH secretion, as generally accepted, but PTH synthesis is also
regulated by serum calcium and 1 ,25(OH)2D both in vitro [3—5]
and in vivo [6, 71. Thus, it has been shown that high ambient
calcium suppresses and low ambient calcium stimulates PTH
synthesis as assessed by the level of PTH mRNA in parathyroid
glands [3, 4, 61 and this suppression is mediated by regulations
of 5'-flanking sequences of the PTH gene [301. Moreover,
I ,25(OH)2D3 also suppresses PTH synthesis at transcriptional
level affecting 5 '-flanking sequences of the PTH gene [311.
Recently, elevated PTH mRNA levels have been demonstrated
in a rat model of chronic renal failure [8], however, limited
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Fig. 1. Serum concentrations of vitamin D metabolites of sham-oper-
ated and chronic renal failure (CRF) rats at 4 weeks after 7/8 nephrec-
zomy. A. 25(OH)D (nglml); B. 1,25(OH)2D (pg/mi); C. 24,25(OH)2D
(ng/ml). There are no significant differences in serum concentrations of
these metabolites between chronic renal failure (N = 12) and sham-
operated rats (N = 9).
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Fig. 5. Serum calcium concentration following 1,25(OH)2D3 adminis-
tration. Serum calcium was measured at the time of sacrifice. Note that
serum calcium rose in response to l,25(OH)2D3 in both chronic renal
failure (El) and sham-operated rats (I). * denotes a significant differ-
ence vs. vehicle treated rats, and ** vs. sham-operated rats given the
same dose of 1 ,25(OH)2D3. Serum Ca increased to higher levels in
chronic renal failure than in sham-operated rats.
Fig. 4. Effect of 1,25(OH)2D3 on FF11 mRNA level in chronic renal
failure rats. A. Each dose of 1,25(OH)2D3 indicated below was given
i.p. at 24 and 48 hours before sacrifice. Ten micrograms of total RNA
from thyro-parathyroid glands of a single rat were analyzed for PTH
mRNA by the primer extension method. Lane 1: vehicle; lane 2: 20
pmolIlOO g body wt per day; lane 3: 40 pmolIlOO g body wt per day; lane
4: 80 pmolIlOO g body wt per day. B. Effect of 1 ,25(OH)2D,, 40 pmoIJlOO
g body wt given twice as in A, on the PTH mRNA level in five chronic
renal failure rats. The PTH mRNA to p-actin mRNA ratio of sham-
operated rats was taken as 100%. The ratio decreased significantly (*
<0.01) in the rats given I ,25(OH)2D3 to the levels seen in normal rats.
information is available regarding the pathogenetic mechanisms
underlying enhanced PTH synthesis in chronic renal failure.
In our rat model of chronic renal failure, hyperplasia of
parathyroid glands and enhanced PTH secretion were seen
already at four weeks of 7/8 nephrectomy, when the serum
creatinine concentration increased only twice the normal. PTH
mRNA levels in parathyroid glands of chronic renal failure rats
were elevated both per RNA and per DNA at this stage of
chronic renal failure. The elevation of the steady state level of
PTH mRNA may suggest the enhanced transcription of the
PTH gene or PTH mRNA stability. Although we have not
carried out the nuclear run-off assay to assess whether the
elevated levels of PTH mRNA is due to stimulation of the PTH
gene transcription or increased PTH mRNA stability, available
data suggest that elevated PTH mRNA levels in chronic renal
failure are due, at least in part, to enhanced transcription of the
FF11 gene [7, 31]. That PTH mRNA levels were elevated both
per RNA and per DNA strongly suggests that not only the
number of cells producing PTJ-I is increased but also FF11
synthesis per cell is increased in parathyroid glands of chronic
renal failuEe rats. Microscopic examination of our specimens
revealed that the content of non-chief cells in parathyroid
glands of sham-operated control rats was at most 20% of the
whole cell number, while in hyperplastic glands of chronic renal
failure rats the great majority was apparently parathyroid chief
cells. We could not determine whether the absolute number of
non-chief cells differs between the glands of normal and chronic
renal failure rats. However, it may not be unreasonable to
assume that the absolute number of non-parathyroid cells in a
gland did not change in chronic renal failure. If this is the case,
our findings of increased PTH mRNA per unit RNA in chronic
renal failure may well represent hyperplastic parathyroid glands
in chronic renal failure, and the increased PTH mRNA per unit
DNA may represent the presence of hypertrophy of chief cells.
In any event, these changes would be significant, even in the
presence of changes in the non-chief cells, considering more
than a 10-fold increase in PTH mRNA. Moreover, the size of
parathyroid glands in uremic rats was considerably larger than
that of normal rats. Thus there is little doubt about the presence
of hyperplasia of parathyroid glands in uremic rats.
It has been shown that 1,25(OH)2D3 given in vivo suppresses
both the levels of PTH mRNA in normal rats 171 and prolifer-
ation of parathyroid cells in uremia [32]. In our chronic renal
failure model rats, administration of 1,25(OH)2D3 could sup-
press the elevated PTH mRNA levels to normal. Since serum
levels of 1 ,25(OH)2D of chronic renal failure rats prior to
administration of 1 ,25(OH)2D3 were not detectably different
from those in normal rats, these data indicate that physiological
concentrations of I ,25(OH)2D in circulation may not effectively
suppress or prevent elevation in PTH mRNA levels or parathy-
roid cell proliferation in chronic renal failure. It is also of note
that the serum calcium concentration was not detectably dif-
ferent between chronic renal failure and control rats, but PTH
mRNA levels were clearly elevated in chronic renal failure rats.
The data suggest that the hypocalcemia might not be the
primary cause of elevated FF11 mRNA levels and that normal
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Fig. 7. Serum calcium concentration after administration of either
1,25(OH)2D3 or 22-oxa-1,25(OH)2D3 in chronic rena/failure rats. Two
hundnred pmolIlOO g body wt of 22-oxa- 1 ,25(OH)2D3 at 24 and 48 hours
prior to sacrifice did not cause hypercalcemia while the same dose of
1 ,25(OH)2D3 caused marked hypercalcemia (*P < 0.01).
Fig. 6. Suppression of PTH mRNA by 22-oxa-l,25(OH)2D3. PTH
mRNA levels were determined by Northern blot. Ten micrograms of
total RNA from thyro-parathyroid glands of a single rat were analyzed.
A. 22-oxa-l ,25(OH)2D3 or vehicle was given i.p. at 24 and 48 hours
before sacrifice. Lane 1: 200 pmoLf 100 g body wt of 1 ,25(OH)2D3; lane
2: vehicle; lane 3: 40 pmolJlOO g body wt of 22-oxa- 1 ,25(OH)2D3; lane 4:
200 pmolIlOO g body wt of 22-oxa-l ,25(OH)2D3. B. Effect of 22-oxa-
l,25(OH)2D3, 200 pmolIlOO g body wt, on the PTH mRNA level in four
chronic renal failure rats. The PTH mRNA to /3-actin mRNA ratio of
sham-operated rat was taken as 100%. The ratio decreased significantly(* < 0.01) in the rats given 22-oxa-1 ,25(OH)2D3 to the levels seen in
normal rats.
serum calcium levels is not sufficient to prevent PTH hyperse-
cretion and synthesis. However, serum calcium and vitamin D
were measured only at one time point of a day when animals
were sacrificed; thus our data do not exclude the possibility that
serum levels of calcium and 1 ,25(OH)2D may have been dif-
ferent at other times of a day, thus stimulating PTH secretion
and synthesis. Also, it is quite possible that within a few days
after nephrectomy there would be a transient fall in serum
1 ,25(OH)2D, thence ionized calcium, before the remnant kidney
compensates by increasing 1 ,25(OH)2D production, phenomena
which could trigger the secondary hyperparathyroidism of
chronic renal failure. That PTH secretion and synthesis are
enhanced in the presence of physiological concentrations of
l,25(OH)2D in the steady state in early chronic renal failure
strongly indicates that parathyroid cells are resistant even in
this stage of chronic renal failure to the physiological concen-
tration of 1 ,25(OH)2D. In a recent study, Shvil and associates
have shown the increased levels of PTH mRNA in a rat model
of chronic renal failure [8], observations similar to our present
results. However, in their study, serum levels of 1 ,25(OH)2D
was clearly decreased, and they suggested that this decrease in
serum 1,25(OH)2D may be responsible for increased PTH
synthesis in renal failure, observations at variance from our
results.
Slatopolsky and associates demonstrated that repetitive i.v.
1 ,25(OH)2D3 administrations could suppress PTH secretion
without causing apparent hypercalcemia in chronic dialysis
patients who had been unresponsive to conventional oral
1 ,25(OH)2D3 therapy [8—10], a regimen which may maintain
normal plasma concentration of I ,25(OH)2D. These observa-
tions suggest the direct suppressive effects of supraphysiologi-
cal concentrations of 1 ,25(OH)2D on PTH secretion. The sup-
pression of the steady state PTH mRNA levels and of plasma
PTH concentrations by i.p. 1 ,25(OH)2D3 in the present study,
though this may be due in part to the concomitant hypercalce-
mia, is similar to that seen in chronic dialysis patients and may
be consistent with a view that the set-point of PTH secretion for
ambient calcium concentrations is shifted to the right in chronic
uremia: thus a higher than normal ambient calcium is necessary
to suppress PTH secretion in chronic uremia. A recent study by
Delmez and associates in chronic dialysis patients show that the
lack of the effect of physiological concentrations of 1 ,25(OH)2D
may be responsible for this shift of the set-point of PTH
secretion for ambient calcium and that supraphysiological con-
centrations of 1 ,25(OH)2D in circulation may be necessary to
correct this shifted set-point of PTH secretion [10]. Our dem-
onstration of elevated PTH mRNA levels in early chronic renal
failure rats, in the presence of normal serum concentrations of
calcium and 1 ,25(OH)2D, and of suppression of the elevated
PTH and mRNA level toward normal by supraphysiological
concentrations of 1 ,25(OH)2D are consistent with these obser-
vations in chronic dialysis patients [9, 10]. Thus, in contrast to
the mechanisms proposed in previous postulates, it is reason-
able to propose that the resistance of parathyroid cells to the
physiological circulating concentration of 1 ,25(OH)2D may be
the primary cause of secondary hyperparathyroidism in the
early phase of chronic renal failure. The cellular mechanisms
underlying this resistance is not clear at present, however, it
may be related to the reduction in the 1,25(OH)2D receptor
density in parathyroid cells of chronic uremia [14, 33, 34]. In
addition, similarities between our present findings in chronic
renal failure rats and those by Slatopolsky and associates in
chronic dialysis patients raise the possibility that the shift of the
set-point of PTH secretion for ambient calcium may already be
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present, albeit subtle and clinically undetectable, in patients
with early to moderate stage of chronic renal failure prior to
chronic dialysis. Further studies are necessary to test these
possibilities.
A synthetic analogue of vitamin D, 22-oxa- 1 ,25(OH)2D3, may
mimic certain actions of I ,25(OH)2D3 on cell differentiation but
may not induce hypercalcemia [35]. Interestingly, Brown and
associates showed recently in normal rats that this vitamin D
analogue could suppress PTH mRNA levels of parathyroid cells
without causing hypercalcemia [15]. Suppression by 22-oxa-
1 ,25(OH)2D3 of PTH secretion without concomitant hypercal-
cemia was also shown by these investigators in uremic dogs
[361. Similar to their observations, our present study clearly
shows that 22-oxa-l ,25(OH)2D3 can suppress the elevated lev-
els of both serum PTH concentrations and PTH mRNA of
parathyroid glands in chronic renal failure rats without causing
hypercalcemia. Suppression of PTH mRNA levels by 22-oxa-
1,25(OH)2D3 was weaker than that by the same dose of
1 ,25(OH)2D3, and this may be due in part to the absence of
hypercalcemia in response to 22-oxa-l ,25(OH)2D3.
Controls of serum levels of inorganic phosphate and calcium,
respectively, by dietary phosphate restriction and by use of the
active vitamin D, either as 1 ,25(OH)2D3 or 1 a(OH)D3, are
central in the management of secondary hyperparathyroidism
of chronic dialysis patients. Aluminum containing antacids had
been used widely to control serum inorganic phosphate levels in
chronic dialysis patients until recently, when it became clear
that aluminum may accumulate in the body leading to dialysis
encephalopathy and incapacitating low turnover bone disease in
chronic dialysis patients [37]. To avoid aluminum accumula-
tion, calcium carbonate has become widely used as a phosphate
binder in the last few years. However, with calcium carbonate,
the risk of hypercalcemia has become a more frequent and
clinically serious side effect of the use of 1 ,25(OH)2D3 or
la(OH)D3, making the hypercalcemia the most restrictive prob-
lem in use of l,25(OH)2D3 or la(OH)D3 in chronic dialysis
patients [38]. In this respect, our present data raise the possi-
bility, as previously proposed by Brown and associates [15, 36],
that 22-oxa- 1 ,25(OH)2D3, given in proper quantities, may be
able to effectively suppress secretion and synthesis of PTH
without the risk of hypercalcemia in chronic dialysis patients,
and thus could be highly useful in the management of secondary
hyperparathyroidism and associated bone diseases of chronic
dialysis patients.
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